Animab is a new venture designed to adress the changing needs of animal production. Using proprietary research discoveries, Animab targets the emerging science and new possibilities in the gut. The interdisciplinary team integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies and sustainability. Led by an experienced group of experts with expertise in a range of relevant domains from vaccines, biotechnology, business management and international marketing, Animab is dedicated to offering a safe and sustainable way to ensure animal performance. More information: www.animab.com
Employees: 1-10
Total raised: $11.76M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | Agri Inves... | aifund.be |
| - | V-Bio Vent... | v-bio.vent... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.07.2025 | Series B | $11.76M | - |
Mentions in press and media 5
| Date | Title | Description |
| 01.07.2025 | Animab Secures EUR 10 Million in Series B Financing | Zwijnaarde, 1 July 2025 – Animab (“the Company”), a leader in pioneering first-in-class oral antibody solutions for unmet needs in production animals, announces the successful closing of a EUR 10 million Series B funding round. The investme... |
| 23.04.2025 | Animab enters into an exclusive distribution agreement with Huvepharma | Zwijnaarde, Belgium, 22 April, 2025 - Animab (“the Company”), a leader in pioneering first-in-class oral antibody solutions for unmet needs in production animals, today announces an exclusive distribution agreement with Huvepharma® (“Huveph... |
| 25.09.2024 | Animab announces Jan Spaas as new Chairman of the Board | Zwijnaarde, Belgium – May 15, 2024: Animab, a front-runner in the field of highly innovative first-in-class oral antibody solutions for unmet needs in production animals, is excited to announce Jan Spaas joined the company’s board as Chairm... |
| 07.07.2023 | Final closing brings Qbic III to 88.5 million euros | St-Denijs-Westrem, Belgium, July, 5th 2023 – Qbic, the Belgian interuniversity venture capital fund that catalyzes the translation of promising technological developments from research institutions to sustainable companies, closes a second ... |
| 09.11.2022 | Qbic III leads Animab's Series A round | Ghent, November 7th, 2022 – Animab, a biotech start-up that is developing a new class of orally administered antibodies for animal health, is excited to announce the successful closing of its Series A round. The proceedings will be used to ... |